Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1139 Results

Title
Intervention Indication Therapeutic Area Year Actions
Sacituzumab govitecan for metastatic or unresectable locally advanced triple-negative breast cancer – third line Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Sacituzumab govitecan for treating HR+/HER2- negative metastatic breast cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2021 View  |  Download
Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2023 View  |  Download
Sacituzumab govitecan for urothelial cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Urothelial cancer Urological Cancer 2022 View  |  Download
Sacubitril-valsartan for previously untreated chronic heart failure with reduced ejection fraction in children Sacubitril-valsartan Chronic heart failure Cardiovascular System 2022 View  |  Download
Sacubitril/valsartan for the treatment of post-acute myocardial infarction patients with left ventricular systolic dysfucntion and/or pulmonary congestion – first line Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan) Post-acute myocardial infarction (MI) Cardiovascular System 2021 View  |  Download
SAGE-547 for super-refractory status epilepticus Brexanolone (SAGE-547; Zulresso) Super-refractory status epilepticus (SRSE) Neurology 2017 View  |  Download
SAR443820 for treating amyotrophic lateral sclerosis (ALS) SAR443820 (DNL788) Amyotrophic lateral sclerosis Neurology 2023 View  |  Download
Sarconeos for treating severe COVID-19 in people aged 45 years and over Sarconeos (BIO101; BIO 101; BIO-101; Ruvembri) COVID-19 Infectious Disease 2024 View  |  Download
1 2 89 90 91 92 93 113 114
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications